NASDAQ:CUE Cue Biopharma (CUE) Stock Price, News & Analysis $0.96 -0.02 (-2.04%) (As of 07/5/2024 08:52 PM ET) Add Compare Share Share Today's Range$0.96▼$1.0750-Day Range$0.96▼$2.1852-Week Range$0.94▼$4.89Volume258,100 shsAverage Volume318,969 shsMarket Capitalization$46.69 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Cue Biopharma alerts: Email Address Cue Biopharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside733.3% Upside$8.00 Price TargetShort InterestBearish9.23% of Shares Sold ShortDividend StrengthN/ASustainability-0.58Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.97) to ($0.92) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.69 out of 5 starsMedical Sector387th out of 879 stocksPharmaceutical Preparations Industry176th out of 417 stocks 3.5 Analyst's Opinion Consensus RatingCue Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCue Biopharma has only been the subject of 2 research reports in the past 90 days.Read more about Cue Biopharma's stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted9.23% of the outstanding shares of Cue Biopharma have been sold short.Short Interest Ratio / Days to CoverCue Biopharma has a short interest ratio ("days to cover") of 15.9, which indicates bearish sentiment.Change versus previous monthShort interest in Cue Biopharma has recently increased by 3.22%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldCue Biopharma does not currently pay a dividend.Dividend GrowthCue Biopharma does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCue Biopharma has received a 74.25% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Preclinical research services for physical health", "Basic medical research services", and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Cue Biopharma is -0.58. Previous Next 0.6 News and Social Media Coverage Search Interest4 people have searched for CUE on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Cue Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cue Biopharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.49% of the stock of Cue Biopharma is held by insiders.Percentage Held by InstitutionsOnly 35.04% of the stock of Cue Biopharma is held by institutions.Read more about Cue Biopharma's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cue Biopharma are expected to grow in the coming year, from ($0.97) to ($0.92) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cue Biopharma is -0.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cue Biopharma is -0.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCue Biopharma has a P/B Ratio of 1.17. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Cue Biopharma's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaThe #1 Crypto That You Don’t Own… YetArtificial Intelligence has revolutionized the way we consume media and entertainment… And the A.I. wave has also created MASSIVE opportunities for savvy investors. One recent move stands out above all others: recently surfaced investments from three major media companies.Click here for all the details… About Cue Biopharma Stock (NASDAQ:CUE)Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.Read More CUE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CUE Stock News HeadlinesMay 30, 2024 | investorplace.comMedical Moonshots: 3 Biotech Stocks Set to SkyrocketMay 16, 2024 | markets.businessinsider.comCue Biopharma’s Promising Future: A Comprehensive Buy Rating JustificationJuly 8, 2024 | Crypto 101 Media (Ad)[Urgent] Hedge Funds Expect Major Crypto MovesIn the year following Bitcoin’s last Halving event, that happened in May of 2020… Bitcoin shot up over 550%. But that’s not all… May 11, 2024 | finance.yahoo.comCue Biopharma First Quarter 2024 Earnings: Beats ExpectationsMay 10, 2024 | markets.businessinsider.comOppenheimer Reaffirms Their Buy Rating on Cue Biopharma (CUE)May 10, 2024 | investorplace.comCUE Stock Earnings: Cue Biopharma Beats EPS, Beats Revenue for Q1 2024May 9, 2024 | finance.yahoo.comCue Biopharma Reports First Quarter 2024 Financial Results and Recent Business HighlightsMay 9, 2024 | finance.yahoo.comCue Biopharma Reports First Quarter 2024 Financial Results and Recent Business HighlightsJuly 8, 2024 | Crypto 101 Media (Ad)[Urgent] Hedge Funds Expect Major Crypto MovesIn the year following Bitcoin’s last Halving event, that happened in May of 2020… Bitcoin shot up over 550%. But that’s not all… May 8, 2024 | globenewswire.comCue Biopharma to Present at the 20th Annual PEGS Boston SummitMay 7, 2024 | finance.yahoo.comCue Biopharma to Participate in Fireside Chat at The Citizens JMP Life Sciences ConferenceApril 24, 2024 | globenewswire.comCue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingApril 9, 2024 | markets.businessinsider.comForecasting The Future: 4 Analyst Projections For Cue BiopharmaApril 9, 2024 | finanznachrichten.deCue Biopharma, Inc.: Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business HighlightsApril 9, 2024 | finance.yahoo.comCue Biopharma Inc (CUE) Q4 2023 Earnings Call Transcript Highlights: Strategic Alliances and ...April 8, 2024 | markets.businessinsider.comCue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business HighlightsApril 8, 2024 | globenewswire.comCue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business HighlightsApril 8, 2024 | msn.comOptions Volatility and Implied Earnings Moves Today, April 08, 2024See More Headlines Receive CUE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cue Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/07/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CUE CUSIPN/A CIK1645460 Webwww.cuebiopharma.com Phone(617) 949-2680FaxN/AEmployees53Year FoundedN/APrice Target and Rating Average Stock Price Target$8.00 High Stock Price Target$10.00 Low Stock Price Target$6.00 Potential Upside/Downside+733.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-50,730,000.00 Net Margins-711.84% Pretax Margin-711.84% Return on Equity-128.30% Return on Assets-77.61% Debt Debt-to-Equity Ratio0.11 Current Ratio2.47 Quick Ratio2.47 Sales & Book Value Annual Sales$5.49 million Price / Sales8.51 Cash FlowN/A Price / Cash FlowN/A Book Value$0.82 per share Price / Book1.17Miscellaneous Outstanding Shares48,640,000Free Float45,000,000Market Cap$46.69 million OptionableOptionable Beta1.96 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Daniel R. Passeri J.D. (Age 63)M.Sc., CEO & Director Comp: $607.98kDr. Anish Suri Ph.D. (Age 50)President & Chief Scientific Officer Comp: $447.34kMs. Kerri-Ann Millar (Age 54)Chief Financial Officer Comp: $447.34kDr. Ronald D. Seidel III (Age 48)Ph.D., Co-Founder Comp: $316.63kMr. Colin G. Sandercock J.D. (Age 67)MSE, Senior VP, General Counsel & Secretary Comp: $381.42kDr. Matteo Levisetti M.D. (Age 55)Chief Medical Officer More ExecutivesKey CompetitorsPrelude TherapeuticsNASDAQ:PRLDEliem TherapeuticsNASDAQ:ELYMAkebia TherapeuticsNASDAQ:AKBA2seventy bioNASDAQ:TSVTRani TherapeuticsNASDAQ:RANIView All CompetitorsInsiders & InstitutionsCarlson Capital L PSold 100,000 shares on 5/14/2024Ownership: 0.041%Vanguard Group Inc.Bought 150,457 shares on 5/10/2024Ownership: 4.694%Monaco Asset Management SAMSold 7,500 shares on 5/9/2024Ownership: 0.688%Wedmont Private CapitalBought 20,000 shares on 4/10/2024Ownership: 0.082%Anish SuriBought 4,000 shares on 8/25/2023Total: $11,040.00 ($2.76/share)View All Insider TransactionsView All Institutional Transactions CUE Stock Analysis - Frequently Asked Questions How have CUE shares performed this year? Cue Biopharma's stock was trading at $2.64 at the start of the year. Since then, CUE shares have decreased by 63.6% and is now trading at $0.96. View the best growth stocks for 2024 here. How were Cue Biopharma's earnings last quarter? Cue Biopharma, Inc. (NASDAQ:CUE) posted its quarterly earnings results on Thursday, May, 9th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.05. The company earned $1.72 million during the quarter, compared to the consensus estimate of $0.73 million. Cue Biopharma had a negative trailing twelve-month return on equity of 128.30% and a negative net margin of 711.84%. How do I buy shares of Cue Biopharma? Shares of CUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Cue Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cue Biopharma investors own include Provention Bio (PRVB), NVIDIA (NVDA), OPKO Health (OPK), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), AbbVie (ABBV) and Gilead Sciences (GILD). This page (NASDAQ:CUE) was last updated on 7/8/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredI’m giving you the name of this investment for freeThis key unlocks a new pathway to wealth that has been kept hidden from you for decades. In my new documen...Porter & Company | SponsoredOperation Replace Biden is a GoLast night’s debate proved me right: Joe Biden will be replaced. I’ve been making this warning for months… ...The Freeport Society | SponsoredBiden to drop out; finish out his term?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Weiss Ratings | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | SponsoredObama’s DNC coupAs we approach the Democratic National Convention in August... many sense a Biden swap-out is looming. In f...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cue Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cue Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
